Sickle Cell Disease-Modifying Therapies
* You will be redirected to the BCM DCPD credit management site when claiming credit and may be asked to register or log in.
In this presentation, Dr. Titilope Fasipe discusses the sickle cell disease-modifying therapies that are utilized at Texas Children's Hospital, as well as the natural history and current landscape of sickle cell disease treatment innovation.
This Texas Children’s Hospital Hematology and Coagulation Conference session took place on Wednesday, January 25, 2023 at 8:00 a.m.
Activity Information
How to Claim Credit
You may claim credit after watching this activity.
You will be redirected to the BCM DCPD credit management site when claiming credit and may be asked to register or log in.
Needs Statement
Physicians, fellows, nurse practitioners, nurses, laboratory technicians, allied health professionals, and other healthcare professionals in the fields of pediatric hematology-oncology, transfusion medicine, and pathology need to receive regular updates on evidence-based approaches to the diagnosis and management of hematologic disorders and coagulopathies and on novel research findings. Reviews of challenging cases will be used as an impetus for discussion. The series aims to increase the knowledge and skills of the learners with regard to the spectrum of hematologic disorders and coagulopathies in order to enhance the quality of care and improve patient outcomes.
Educational Objectives
At the conclusion of the session, the participants should be able to:
- Summarize the clinical course and chronic nature of sickle cell disease.
- Describe historical and systemic barriers to innovative therapies for sickle cell disease.
- Identify and differentiate between current and emerging therapies for sickle cell disease.
Target Audience
Professional Categories
- Physicians
- Fellows
- Nurses
- Other Health Professionals
Specialties
- Family and Community Medicine
- Hematology
- Internal Medicine
- Pediatrics
Interest Groups
- Hospital Medicine
Activity Evaluation
Evaluation by questionnaire will address program content, presentation, and possible bias.
Educational Methods
- Lectures
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Director
Term of Approval
January 1, 2023 through January 31, 2025. Original release date: January 1, 2023.
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenter
-
Titilope Fasipe, M.D., Ph.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
- Consultancy: Bluebird Bio; Emmaus Medical; Forma Therapeutics; Global Blood Therapeutics; Novartis
Activity Director
-
Jacquelyn M. Powers, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
- Consultancy: Pharmacosmos LLC
Planning Committee Members
-
-
Chelsea Daignault, M.D.
Pediatric Hematology-Oncology Fellow
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
YoungNa Lee-Kim, M.D.
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Jacquelyn M. Powers, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
- Consultancy: Pharmacosmos LLC
Health Topics
Presenter: